SBIR/STTR Research Award
A Cell-Penetrating Anthrax Antitoxin
Award amount
$219,367Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Planet Biotechnology Incorporated
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- KTJKPBE2H5H3
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): The goal of this research is to develop an economical, safe, effective therapy to reverse the activity of the catalytic component, LF, of the Bacillus anthracis toxin (lethal toxin), within the cytoplasm of the intoxicated cell. Success in achieving this goal will lead to better outcomes than currently seen with antibiotics or antitoxins like raxibacumab or PBI-220, and this could save countless more lives in the event of a bioterrorist attack with B. anthracis. We propose to screen the humanized camelid library to identify high-affinity single chain variable fragment, a nanobody, able to block protease activity of lethal factor (LF). We will then create genetic fusion of the nanobody that blocks LF with another domain of LF, LFN, that had the translocating activity buts is devoid of catalytic activity to enable it to be transported into the cytoplasm of mammalian cells in the presence of PA. Thus, we plan to co-opt the B. anthracis toxin delivery system to deliver,
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A broad spectrum anti-gonorrhea immunotherapeutic
- Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections
- Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease
- Bispecific antibody for topical administration to prevent gonorrhea
- Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
38 SBIR/STTR records share this UEI (2000–2024). Reported award amounts total $26,790,475. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense, Department of Agriculture